Evaluation of Recombinant Attenuated Salmonella Vaccine Strains for Broad Protection against Extraintestinal Pathogenic Escherichia coli by Maddux, Jacob (ASU author) et al.
October 2017 | Volume 8 | Article 12801
Original research
published: 09 October 2017
doi: 10.3389/fimmu.2017.01280
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Lee Mark Wetzler, 
Boston University School of 
Medicine, United States
Reviewed by: 
Raffael Nachbagauer, 
Icahn School of Medicine at 
Mount Sinai, United States  
Scott D. Gray-Owen, 
University of Toronto, Canada
*Correspondence:
Melha Mellata 
mmellata@iastate.edu
†Present address: 
Jacob T. Maddux, 
Mayo Clinic, Scottsdale, 
AZ, United States; 
Roy Curtiss III, 
Department of Infectious Diseases 
and Pathology, University of Florida, 
Gainesville, FL, United States
‡These authors have contributed 
equally to this work.
Specialty section: 
This article was submitted to 
Vaccines and Molecular 
Therapeutics, 
a section of the journal 
Frontiers in Immunology
Received: 09 May 2017
Accepted: 25 September 2017
Published: 09 October 2017
Citation: 
Maddux JT, Stromberg ZR, 
Curtiss R III and Mellata M (2017) 
Evaluation of Recombinant 
Attenuated Salmonella Vaccine 
Strains for Broad Protection 
against Extraintestinal 
Pathogenic Escherichia coli. 
Front. Immunol. 8:1280. 
doi: 10.3389/fimmu.2017.01280
evaluation of recombinant 
attenuated Salmonella Vaccine 
strains for Broad Protection  
against extraintestinal  
Pathogenic Escherichia coli
Jacob T. Maddux1†‡, Zachary R. Stromberg2‡, Roy Curtiss III1,3† and Melha Mellata1,2*
1 The Biodesign Institute, Arizona State University, Tempe, AZ, United States, 2 Department of Food Science and Human 
Nutrition, Iowa State University, Ames, IA, United States, 3 School of Life Sciences, Arizona State University, Tempe, AZ, 
United States
Antibiotic-resistant bacterial infections are difficult to treat, producing a burden on 
healthcare and the economy. Extraintestinal pathogenic Escherichia coli (ExPEC) strains 
frequently carry antibiotic resistance genes, cause infections outside of the intestine, and 
are causative agents of hospital-acquired infections. Developing a prevention strategy 
against this pathogen is challenging due to its antibiotic resistance and antigenic diversity. 
E. coli common pilus (ECP) is frequently found in ExPEC strains and may serve as a 
common antigen to induce protection against several ExPEC serotypes. In addition, live 
recombinant attenuated Salmonella vaccine (RASV) strains have been used to prevent 
Salmonella infection and can also be modified to deliver foreign antigens. Thus, the 
objective of this study was to design a RASV to produce ECP on its surface and assess 
its ability to provide protection against ExPEC infections. To constitutively display ECP in a 
RASV strain, we genetically engineered a vector (pYA4428) containing aspartate-β-semi-
aldehyde dehydrogenase and E. coli ecp genes and introduced it into RASV χ9558. 
RASV χ9558 containing an empty vector (pYA3337) was used as a control to assess 
protection conferred by the RASV strain without ECP. We assessed vaccine efficacy 
in in  vitro bacterial inhibition assays and mouse models of ExPEC-associated human 
infections. We found that RASV χ9558(pYA4428) synthesized the major pilin (EcpA) 
and tip pilus adhesin (EcpD) on the bacterial surface. Mice orally vaccinated with RASV 
χ9558(pYA3337) without ECP or χ9558(pYA4428) with ECP, produced anti-Salmonella 
LPS and anti-E. coli EcpA and EcpD IgG and IgA antibodies. RASV strains showed 
protective potential against some E. coli and Salmonella strains as assessed using in vitro 
assays. In mouse sepsis and urinary tract infection challenge models, both vaccines had 
significant protection in some internal organs. Overall, this work showed that RASVs can 
elicit an immune response to E. coli and Salmonella antigens in some mice, provide sig-
nificant protection in some internal organs during ExPEC challenge, and thus this study 
is a promising initial step toward developing a vaccine for prevention of ExPEC infections. 
Future studies should optimize the ExPEC antigens displayed by the RASV strain for a 
more robust immune response and enhanced protection against ExPEC infection.
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TaBle 1 | Bacterial strains and plasmids.
strain or 
plasmid
relevant genotype, phenotype,  
and characteristics
reference
Salmonella enterica
χ3444 Salmonella Typhi This study
χ3761 Salmonella Typhimurium UK-1 (24)
χ8387 Salmonella Paratyphi (25)
χ9558 Δpmi-2426 Δ(gmd-fcl)-26 ΔPfur81:TT araC PBAD fur 
ΔPcrp527:TT araC PBAD crp ΔasdA27:TT araC PBAD c2 
ΔaraE25 ΔaraBAD23 ΔrelA198:araC PBAD lacI TT 
ΔsopB1925 ΔagfBAC811
(21)
Escherichia coli
χ6212 ΔasdA DH5α derivative (26)
E24377A Human enterotoxigenic E. coli (27)
CFT073 UPEC, O6:K2:H1, ST73, acute pyelonephritis (23)
JJ1886 UPEC, O25b:H5, ST131, fatal urosepsis (28)
UTI89 UPEC, O18:K1:H7, ST95, Cystitis (29)
RS218 NMEC, O18:K1:H7, ST95 (30)
HS-4 Human non-pathogenic commensal, O9:H4 (29)
J198 Human non-pathogenic commensal, O22 (31)
Nissle 1917 Human non-pathogenic commensal, O6:K5:H1 (32)
MG1655 Laboratory strain of E. coli K-12, OR:K-:H48 (29)
Plasmid
pCR-XL-
TOPO
3.5 kb pUC ori cloning vector, Kanamycin  
resistance
Invitrogen
pYA3337 asd-based cloning vector (pSC101 ori) with Ptrc 
promoter
(33)
pYA4428 The ecpABCD was cloned under Ptrc of pYA3337 This study
NMEC, neonatal meningitis E. coli; ST, sequence type; UPEC, uropathogenic E. coli.
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inTrODUcTiOn
Extraintestinal pathogenic Escherichia coli (ExPEC) is a 
heterogeneous group of bacteria that causes extraintestinal 
diseases in humans and costs the US healthcare system over $1 
billion annually (1). Human ExPEC strains can be subclassi-
fied into neonatal meningitis-causing E. coli, sepsis-associated 
E. coli, and uropathogenic E. coli that causes urinary tract 
infections (UTIs). In the US, ExPEC infections account for 
17% of severe sepsis cases, are the primary cause of commu-
nity-acquired UTI, and cause ~50% of nosocomial UTI (2, 3). 
Antibiotic-resistant ExPEC strains complicate treatment of 
these infections (4), but vaccination as an alternative to anti-
biotic treatment or a combined strategy against ExPEC may 
have a significant benefit to public health (5–7). Currently, no 
licensed vaccine exists for prevention of ExPEC in humans 
and those developed have lacked immunogenicity, safety, and 
cross-protectiveness (5).
Effective vaccine targets should be broadly protective against 
several ExPEC serotypes. E. coli common pilus (ECP) is an 
extracellular adhesin frequently present in E. coli and some other 
Enterobacteriaceae, e.g., Enterobacter cancerogenus, Klebsiella 
pneumoniae, and Serratia odorifera (8, 9). The ecpRABCDE 
operon encodes for a transcriptional regulator (EcpR), a major 
Pilin (EcpA), a putative chaperone (EcpB), an usher (EcpC), 
a tip pilus adhesin (EcpD), and a potential chaperone (EcpE) 
(8). In E. coli, ECP promotes biofilm formation on inert sur-
faces and contributes to colonization of human epithelial cell 
lines in  vitro (8–13). Mutant ecp ExPEC strains have reduced 
ability to invade ex vivo mouse bladders (13). Virulence was 
also reduced in an avian pathogenic E. coli mutant ecp strain 
that had decreased ability to cause sepsis in chickens (10). 
Vaccination with ECP recombinant antigens was protective in 
a lethal mouse sepsis model (14). Additionally, ECP was pro-
duced in E. coli in urine samples from patients with UTI (13). 
These studies lend evidence that ECP may be a good vaccine 
antigen.
A vaccine that could provide protection against multiple 
pathogens would be highly desired considering its potential wide 
use and economic benefits. Antigen delivery by recombinant 
attenuated Salmonella vaccine (RASV) strains has been used to 
induce immune responses against both the carrier Salmonella 
and foreign protective antigens from bacteria, viruses, and pro-
tozoa (15–20). RASVs can be delivered orally, which eliminates 
use of needles and syringes, and thus is an affordable choice 
for mass vaccination. Recently developed RASVs have the 
advantage of multiplying like wild-type organisms in the early 
phase of colonization and become avirulent following invasion 
into internal organs (15, 20). The objectives of this study were 
to (i) genetically engineer a RASV strain to synthesize and 
display E. coli EcpA and EcpD antigens; (ii) assess the ability 
of the RASV to elicit serum and mucosal immune responses in 
mice; (iii) evaluate the protective potential of the RASV against 
ExPEC and Salmonella using in vitro assays; and (iv) assess the 
RASV protective ability in animal models of ExPEC-associated 
human sepsis and UTI.
MaTerials anD MeThODs
ethics statement
This study was carried out in accordance with the recommen-
dations of Arizona State University Institutional Animal Care 
and Use Committee. The protocol (#1168R) was approved by 
the Arizona State University Institutional Animal Care and Use 
Committee. Six-week-old female BALB/c mice (Charles River 
Laboratories, Wilmington, MA, USA) and 4-week-old female 
CBA/J mice (Jackson Laboratories, Bar Harbor, ME, USA) were 
obtained for infection experiments. Mice were acclimated for 
7 days before experiments began. During the experiments, ani-
mals were monitored twice daily by our team, animal caretakers, 
and further inspected by a veterinarian.
Bacterial strains, Plasmids, and  
growth conditions
Strains and plasmids used are listed in Table  1. Strains were 
stored as stock cultures at −80°C in peptone-glycerol medium. 
Unless otherwise specified, strains were grown in lysogeny 
broth (LB) containing 0.1% glucose. Salmonella enterica serovar 
Typhimurium attenuated strain χ9558, derived from the virulent 
S. Typhimurium strain UK-1 (χ3761), using strategies that 
enhance safety and immunogenicity (21, 22), was used to deliver 
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ECP. Urosepsis strain CFT073 (23) was used in animal challenge 
experiments. ExPEC strains CFT073, JJ1886, UTI89, and RS218, 
non-pathogenic E. coli strains HS-4, J198, and Nissle 1917, labora-
tory E. coli MG1655, and S. Typhi χ3444, S. Typhimurium χ3761, 
and S. Paratyphi χ8387 strains were used for in vitro assays.
Recombinant attenuated Salmonella vaccine strains and 
chal lenge strain CFT073 were grown statically overnight in 
LB. The next day, the culture was inoculated 1:100 into fresh 
LB. RASV strains were grown with aeration at 37°C to OD600 
of ~0.85. CFT073 was grown with aeration at 37°C to OD600  
of ~0.85 (sepsis challenge) or statically overnight (intraurethral 
challenge). Strains were harvested by centrifugation at 24°C 
and resuspended in PBS.
construction of asd-Positive ecp  
Plasmid Vaccine Vector
Fragment ecpABCD, a 5622 bp portion of the ecp operon com-
prising ecpRABCDE, was PCR-amplified from genomic DNA 
of E. coli strain E24377A using KlenTaq LA DNA Polymerase 
(DNA Polymerase Technology, Inc., Saint Louis, MO, USA) 
and primer sets: P1: ecpA (BsrGI)-F: 5′ TAGTAATGTACATGA 
AAAAAAAGGTTCTGGCAATAG 3′ and P2: ecpD (HindIII)-R: 
5′ CCCAAGCTTGGGTTAGTTAATGTTACGCCACCGTCGC 
C 3′ (Figure S1 in Supplementary Material). The amplified frag-
ment included the 5′ region of the first gene, ecpA, from its start 
codon through the stop codon of the last gene, ecpD. To introduce 
the enzyme recognition site for BsrGI into vector pYA3337, we 
amplified the vector plasmid using primer sets: P3: pYA3337 
(HindIII) F 5′ CCACAAGCTTGGCTGTTTTGGCGGATGAGA 
3′ and P4: pYA3337 (BsrGI) R 5′ CCTATGTACATGTTTCCT 
GTGTGAAATTG 3′. The amplified fragment included at the 5′ 
region, the enzyme restriction site HindIII, and at the 3′ region, 
the enzyme restriction site BsrGI. PCR products were cloned 
into the pCR-XL-TOPO vector according to the manufacturer’s 
instructions (Invitrogen).
PCR products of asd-positive vector pYA3337 (BsrG1-
positive) and ecpABCD fragment cloned into the pCR-XL-TOPO 
were cut using HindIII and BsrGI enzymes, respectively. 
DNA bands of the digested ecpABCD(HindIII, BsrGI) and pYA3337 
(HindIII, BsrGI) were purified from an agarose gel and ligated together 
using T4 DNA ligase (New England Biolabs, Ipswich, MA, 
USA) to generate plasmid pYA4428. Plasmids were verified 
by PCR, on agarose gel, restriction digestion analysis with 
HindIII and BsrGI, and sequencing.
The recombinant plasmid was first introduced into E. coli 
strain χ6212 commonly used for synthesis of foreign proteins 
(26). The purified plasmid obtained from χ6212 was then 
electroporated into competent cells of asd-negative Salmonella 
vaccine strain χ9558 to obtain the balanced-lethal construct. 
Selection for transformants was achieved by growth on LB agar 
plates and verified by PCR amplification.
evaluation of ecP synthesis
Bacterial ECP synthesis was evaluated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blot with rabbit anti-EcpA and -EcpD antibodies. The 
E. coli strain E24377A was used as a positive control and χ9558 
containing ecpABC, ecpABCD, or ecpRABCDE were tested to 
determine which portion of the operon maintains ECP synthe-
sis. χ9558 containing ecpABC or ecpRABCDE were constructed 
using the aforementioned methods. Surface display of ECP was 
visualized by transmission electron microscopy (TEM) using 
rabbit anti-EcpA and -EcpD antibodies and goat anti-rabbit 
IgG with 10  nm colloidal gold (MP Biomedicals, Santa Ana, 
CA, USA) at a concentration of 1:250 (9).
Vaccination and antibody responses
Mice were orally (behind the incisors) administered 20  µl 
using a pipette containing either PBS (unvaccinated), 109 CFU 
of χ9558(pYA3337) that carries the asd-plasmid with no ecp 
genes, or 109 CFU χ9558(pYA4428) that carries the asd-plasmid 
with ecpABCD (Figure S2 in Supplementary Material). Before 
immunization, mice were deprived of food and water for 4 h and 
resupplied 30 min after vaccination. Serum was obtained at days 
20 and 41 (BALB/c mice) and days 20 and 30 (CBA/J mice) post-
immunization from blood collected from the submandibular 
vein. Vaginal wash samples were obtained at days 28 and 41 
(BALB/c mice) and day 28 (CBA/J mice) by repeated flushing 
of the vaginal tract and aspiration of 50 µl of PBS. Serum IgG 
and vaginal IgA and IgG responses against ECP proteins and 
Salmonella LPS were determined by ELISA as described previ-
ously (14). Briefly, E. coli antigens were PCR amplified and cloned 
into pET-101/D-TOPO vectors (Invitrogen) and expressed in E. 
coli strain BL21 as His-tagged proteins. Proteins were purified 
using ProBond Ni-NTA resin columns (Invitrogen). Endotoxin 
removal spin columns (Pierce Biotechnology, Rockford, IL, 
USA) were used to remove any remaining LPS from purified 
proteins. Commercial S. Typhimurium LPS (Sigma) was used 
as a source of LPS. Plates were coated at a concentration of 
2.0  µg/ml of antigen and incubated overnight at 4°C. The 
remaining steps were performed at room temperature. Plates 
were washed with PBS containing 0.05% Tween-20 and blocked 
for 1 h with SEA BLOCK (Thermo Scientific). Serum or vaginal 
wash samples were added at 1:50 or 1:10, respectively. Samples 
were diluted twofold down the plate, incubated for 1  h, and 
washed. Goat anti-mouse IgG for serum and day 41 vaginal 
wash samples from BALB/c mice (1:5,000; Southern Biotech, 
Birmingham, AL, USA) or goat anti-mouse IgA for all vaginal 
wash samples (1:5,000; Southern Biotech) was added and plates 
were incubated for 1 h. Plates were washed, and streptavidin, 
alkaline phosphatase conjugate (1:2,000; Southern Biotech) was 
added and incubated for 1  h. After incubation and washing, 
p-nitrophenyl phosphate (Thermo Scientific) was added accord-
ing to the manufacturer’s protocol. The reaction was stopped 
with 2 N NaOH and plates were read at 405 nm. The endpoint 
titer was set as the reciprocal of the highest dilution that gave 
an OD405 twice that of the unvaccinated control.
Antibodies elicited against ECP were further evaluated by 
Western blot. Serum collected on day 41 was pooled in equal 
amounts from 10 mice per group. From unvaccinated, χ9558 
(pYA3337) and χ9558(pYA4428) immunized BALB/c mice 
pooled serum was used as a substitute for rabbit anti-EcpA to 
probe against purified EcpA by Western blot as described above.
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serum and Vaginal Wash Bacterial 
inhibition assays
Bacterial inhibition was tested using bacterial strains (Table 1) 
in pooled (n =  8/group, in equal volumes) serum or vaginal 
wash samples obtained on day 41 from BALB/c mice. Bacterial 
colonies from a fresh LB agar plate were suspended in M9 mini-
mal media until OD600 reached 0.1. The suspension was diluted 
in M9 media (1 ×  102  CFU), mixed with an equal volume of 
pooled serum or vaginal wash samples, and incubated at 37°C 
for 6 h. After incubation, the mixture was serially diluted and 
plated on MacConkey agar to determine viable counts. Samples 
were tested in duplicate in two independent experiments.
Protection studies
Mouse models of human sepsis and UTI were used to evaluate 
the protective ability of RASV immunization. For the mouse 
sepsis model, BALB/c mice were intraperitoneally challenged 
with 100  µl of PBS containing 108  CFU of CFT073 on day 41 
postvaccination. Previously, 100% lethality was observed in a 
mouse sepsis model using 108 CFU of CFT073 by 7 days postchal-
lenge (34). In order to quantitatively determine bacterial loads 
in internal organs, previous studies have used early endpoints 
of 24–48 h postchallenge with CFT073 (35, 36). Therefore, mice 
were euthanized before lethality at 24 h postchallenge, and blood, 
liver, and spleen were collected, serially diluted, and plated on 
MacConkey agar for enumeration of E. coli.
For the mouse UTI model, CBA/J mice were intraperitoneally 
anesthetized with a cocktail of ketamine (100 mg/kg), xylazine 
(10  mg/kg), and acepromazine (2.5  mg/kg) and the bladder 
was emptied by gentle pressure on the abdomen. The median 
infection dose for transurethral inoculation of CFT073 was 
determined previously as 106 CFU/mouse (35). To ensure infec-
tion, mice were inoculated with 50 µl of PBS containing 108 CFU 
of CFT073 via transurethral catheterization using a sterile poly-
ethylene catheter (Intramedic, Becton Dickinson, Sparks, MD, 
USA) on day 28 postvaccination. At 48  h postchallenge, mice 
were euthanized and bladder, kidney, liver, and spleen samples 
were collected, serially diluted, and plated on MacConkey agar 
for enumeration of E. coli.
statistical analysis
An ANOVA followed by Tukey’s test for multiple comparisons 
was used to compare between groups for ELISAs, in  vitro  
sera and vaginal wash assays, and the sepsis and UTI models. 
Fisher’s exact test (two-tailed) was used to compare treatments 
for the proportion of tissues positive for E. coli in the UTI mouse 
model. Analyses were carried out in GraphPad Prism 6.0. 
P values <0.05 were considered significant.
resUlTs
ecP synthesis in rasV strain 
χ9558(pYa4428)
As screened on the SDS-PAGE gel stained with Coomassie 
blue and Western blot (Figure S3 in Supplementary Material), 
ECP production was detected in χ9558(pYA4428) but not in 
χ9558(pYA3337). EcpA and EcpD were displayed on the surface 
of χ9558(pYA4428) as shown by TEM (Figure S4 in Supple-
mentary Material).
level of antigen-specific antibodies 
elicited in BalB/c and cBa/J Mice
To assess immune responses to vaccination, serum and vaginal 
wash samples from 8 to 10 individual mice per treatment were 
evaluated by ELISA for anti-Salmonella LPS and anti-E. coli 
(EcpA and EcpD) antibodies. For BALB/c mice on day 20, only 
one mouse vaccinated with χ9558(pYA4428) elicited anti-EcpA 
and EcpD IgG antibodies, and no IgG antibodies were observed 
for LPS (Figure 1). On day 28, no IgA antibodies were detected 
in vaginal wash samples or if elicited were below the limit of 
detection in the ELISA. On day 41, some mice vaccinated with 
χ9558(pYA3337) or χ9558(pYA4428) elicited IgG and IgA 
antibodies to all three antigens, except that no IgG antibod-
ies were detected against EcpA from vaginal wash samples 
of χ9558(pYA3337) immunized mice. Although some RASV 
immunized mice had elevated antibody titers compared with 
unvaccinated mice, no significant differences were observed 
between vaccinated and unvaccinated mice or between vaccina-
tion groups.
For CBA/J mice on day 20, serum and vaginal wash samples 
from ten individual mice per group were tested by ELISA. Only 
one χ9558(pYA4428) vaccinated mouse but not χ9558(pYA3337), 
elicited anti-EcpA IgG antibodies, one χ9558(pYA3337) and 
two χ9558(pYA4428) immunized mice elicited anti-EcpD IgG 
antibodies, and no anti-LPS IgG antibodies were observed 
(Figure 2). Similar to unvaccinated mice, anti-LPS, anti-EcpA, 
and anti-EcpD IgA antibodies were not detected in vaginal washes 
of vaccinated mice on day 28. On day 30, one χ9558(pYA3337) 
and two χ9558(pYA4428) immunized mice elicited anti-LPS 
IgG antibodies, two χ9558(pYA3337) and one χ9558(pYA4428) 
immunized mice elicited anti-EcpA IgG antibodies, and three 
χ9558(pYA3337) and two χ9558(pYA4428) immunized mice 
elicited anti-EcpD IgG antibodies.
To determine whether antibodies against ECP were 
also detected by Western blot, pooled serum collected from 
BALB/c mice (n = 10/group) was used to probe purified EcpA. 
Western blot analysis showed no reaction to purified EcpA 
when probed with serum extracted from unvaccinated or 
χ9558(pYA3337) immunized mice (Figure S5 in Supplementary 
Material). A positive reaction was observed for serum from 
χ9558(pYA4428) immunized mice. Thus, we confirmed our 
ELISA results for χ9558(pYA4428) but could not confirm our 
results for χ9558(pYA3337) by Western blot.
inhibitory effect of Mouse sera  
and Vaginal Wash samples on  
Bacterial strains
Pooled mouse serum and vaginal wash samples from 10 mice 
by group were mixed with bacterial strains and incubated for 
6  h to determine whether antibodies or other antimicrobial 
products elicited from RASV immunization influenced bacte-
rial levels. These assays were used to test inhibitory activity of 
FigUre 1 | Antibody responses against Salmonella LPS and Escherichia coli common pilus antigens in vaccinated BALB/c mice. Data represent (a–c) serum  
IgG (D–F) vaginal wash IgA, and (g–i) vaginal wash IgG antibody levels induced in BALB/c mice immunized with PBS, χ9558(pYA3337), or χ9558(pYA4428). 
Individual samples from 8 to 10 mice per treatment were analyzed by ELISA against Salmonella LPS and E. coli EcpA and EcpD. Day 28 vaginal wash samples  
were not tested (NT) for IgG. Bars represent the mean and each dot represents an individual mouse. The horizontal dashed line represents the limit of detection 
(LOD). Samples that tested negative were assigned a value halfway between zero and the LOD. Error bars represent SDs.
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serum and vaginal wash samples against multiple pathogenic 
bacterial strains including ExPEC and Salmonella strains not 
tested in vivo and non-pathogenic E. coli strains that represent 
organisms inherent in the gastrointestinal tract of humans. 
A limited amount of sera was collected during the study, and 
therefore, heat-inactivation of sera was not used as a control. 
Generally, sera from mice vaccinated with χ9558(pYA4428) had 
the strongest inhibition against strains (Figure 3). The urosepsis 
strain JJ1886 was significantly decreased in serum samples of 
both χ9558(pYA3337) and χ9558(pYA4428) vaccinated mice 
compared with unvaccinated mice (Figure  3A). A significant 
decrease was also observed in serum of χ9558(pYA4428) 
compared with χ9558(pYA3337) immunized mice. The neo-
natal meningitis-causing E. coli strain RS218 was significantly 
decreased in serum from χ9558(pYA4428) immunized mice 
but not χ9558(pYA3337) compared with unvaccinated mice. 
A significant decrease in levels of RS218 was detected in serum 
of χ9558(pYA4428) compared with that of χ9558(pYA3337) 
immunized mice. No significant differences were observed for 
urosepsis strain CFT073 or laboratory E. coli strain MG1655 
between treatments.
Cervicovaginal lavage samples from healthy women have 
been shown to inhibit growth of E. coli ex vivo (37). To determine 
if RASV immunization influences bacterial inhibition, various 
ExPEC, Salmonella, and non-pathogenic E. coli strains were 
tested for growth in vaginal wash samples (Figure 3B). Two of 
three ExPEC strains (CFT073 and JJ1886) were significantly 
reduced in vaginal washes from χ9558(pYA4428) immunized 
mice but not χ9558(pYA3337) compared to unvaccinated mice. 
One of three Salmonella strains (S. Typhi χ3444), two of three 
commensal non-pathogenic E. coli strains (HS-4 and J198), and 
laboratory E. coli strain MG1655 had significantly decreased 
levels in vaginal washes from χ9558(pYA4428) vaccinated 
mice but not in that of χ9558(pYA3337) compared to unvac-
cinated mice. No significant differences were detected between 
χ9558(pYA3337) vaccinated and unvaccinated mice or between 
any of the treatments for ExPEC strain UTI89, S. Typhimurium 
χ3761, S. Paratyphi χ8387, and E. coli Nissle 1917.
FigUre 3 | Bacterial inhibition of serum and vaginal wash samples from BALB/c mice. (a) Serum or (B) vaginal wash samples were mixed 1:1 with bacterial strain 
cultures and incubated at 37°C for 6 h. After incubation, mixtures were plated on MacConkey agar for bacterial enumerations. Bacterial levels between groups were 
compared by an ANOVA followed by Tukey’s method for multiple comparisons. P values <0.05 were considered significant. Error bars represent SDs.
FigUre 2 | Antibody responses against Salmonella LPS and Escherichia coli common pilus antigens in vaccinated CBA/J mice. Data represent (a–c) serum IgG 
and (D) vaginal wash IgA antibody levels induced in CBA/J mice immunized with PBS, χ9558(pYA3337), or χ9558(pYA4428). Individual samples from 10 mice per 
treatment were analyzed by ELISA against Salmonella LPS and E. coli EcpA and EcpD. Bars represent the mean and each dot represents an individual mouse.  
The horizontal dashed line represents the limit of detection (LOD). Samples that tested negative were assigned a value halfway between zero and the LOD.  
Error bars represent SDs.
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Vaccine Protection against cFT073 
challenge in Mice
After vaccination, all mice survived and no clinical signs of 
disease due to Salmonella infection (diarrhea, weight loss, etc.) 
were observed. In the mouse model of sepsis, BALB/c mice were 
intraperitoneally challenged with 108 CFU of CFT073 to assess 
the efficacy of vaccine treatment against systemic infection. 
BALB/c mice were selected based on past sepsis studies using 
FigUre 4 | Effect of vaccination on extraintestinal pathogenic Escherichia 
coli strain CFT073 ability to cause sepsis in mice. Female BALB/c mice were 
immunized with PBS, χ9558(pYA3337), or χ9558(pYA4428), challenged 
intraperitoneally with 108 CFU of CFT073, and assessed 24 h postchallenge 
for bacterial concentration in the blood, liver, and spleen. Each experimental 
group contained 10 mice. Each dot represents an individual mouse and 
vertical dashed lines separate sample type. Bacterial loads of mice between 
groups were compared by an ANOVA followed by Tukey’s method for 
multiple comparisons. P values <0.05 were considered significant. Error bars 
represent SDs.
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this genetic background to evaluate ExPEC vaccines (36, 38). 
The only significant difference relating to bacterial loads in the 
mouse sepsis model was in the spleen of mice vaccinated with 
χ9558(pYA3337) (Figure 4).
In the UTI mouse model, CBA/J mice were intraurethrally 
challenged with 108 CFU of CFT073 to determine the impact of 
vaccination on bacterial loads in urinary system organs (blad-
der and kidney) and other internal organs (liver and spleen) 
(Figure 5). CBA/J mice were selected based on an established 
UTI protocol (39) to assess the efficacy of vaccine treatment 
against UTI, and to assess whether a different genetic back-
ground resulted in a response similar to RASV immunization 
of BALB/c mice. In general, mice vaccinated with RASV strains 
had numerically lower bacterial loads in organs. Significantly 
lower bacterial loads than unvaccinated mice were observed in 
the bladder for both χ9558(pYA3337) and χ9558(pYA4428). 
Also, χ9558(pYA4428) but not χ9558(pYA3337) vaccinated 
mice had significantly fewer number of E. coli-positive blad-
der samples than unvaccinated mice. In the kidney, liver, and 
spleen, bacterial loads for both χ9558(pYA3337) and χ9558 
(pYA4428) were not significantly different than unvaccinated 
mice. However, for the liver, χ9558(pYA4428) vaccinated mice 
had significantly fewer number of E. coli-positive samples 
than χ9558(pYA3337), but was not significantly different from 
unvaccinated mice.
DiscUssiOn
Recombinant attenuated Salmonella vaccine strains colonize the 
intestinal mucosa and other lymphoid tissues to elicit muco-
sal and systemic immunity, which is important for protection 
against an invasive pathogen like ExPEC (40). Previously, 
RASV χ9558 delivering a pneumococcal antigen replicated and 
colonized the Peyer’s patches, spleen, and liver of mice for at 
least 3 weeks post-vaccination (41). Also, as used in the current 
study, RASV strains with a regulated delayed lysis in vivo system 
colonize the spleen at levels around 105  CFU 1-week postim-
munization (15). After RASV immunization, sufficient time 
and successful display of the antigen is needed for the develop-
ment of a humoral response. Other studies have used type II 
and III secretion systems for RASV surface display of foreign 
antigens (41–44). Here, by cloning ecpABCD genes into the 
asd-based low copy vector pYA3337, E. coli chaperone EcpB 
and usher EcpC successfully displayed EcpA and EcpD on the 
surface of RASV χ9558(pYA4428). Using one plasmid to syn-
thesize two different antigens and displaying them on the RASV 
surface is unique and could be used with other antigens for 
applications in biotechnology, microbiology, and vaccinology.
An immune response is a key component of an effective vac-
cine. As expected, vaccination with χ9558(pYA4428) elicited 
both anti-Salmonella LPS and anti-E. coli ECP antibodies in 
mice. Anti-EcpA antibodies were detected in mice vaccinated 
with χ9558(pYA4428) earlier than other treatments, which 
suggests inclusion of ECP in the RASV may elicit a faster 
immune response to some E. coli antigens. However, the ability 
of χ9558(pYA3337) to elicit anti-EcpA and -EcpD antibodies 
indicates cross-immunity between Salmonella and E. coli. There 
was a lack of evidence that anti-EcpA and -EcpD antibodies 
could bind to χ9558(pYA3337) based on Western blot and TEM. 
In addition, no reaction was observed when purified EcpA was 
probed with serum from χ9558(pYA3337). Previously, serum 
IgG cross-reactivity was demonstrated in RASV immunized 
mice against E. coli outer membrane proteins probably due to 
cross-reactivity of iron regulated outer membrane proteins (45), 
but to our knowledge, ECP or another homologous fimbria 
has not been reported in Salmonella. Anti-EcpA and -EcpD 
antibodies could be elicited by Salmonella antigens that share 
common conformational epitopes with ECP, which warrants 
future study.
Previously developed vaccines against ExPEC were 
tested mainly in BALB/c mice (36, 46–48); in this study, we 
evaluated our vaccines in both BALB/c and CBA/J mice. Slight 
differences in immune responses between mouse strains vac-
cinated with the same RASV could be due to a difference in 
Salmonella susceptibility. Contrary to BALB/c, CBA/J mice 
are considered more resistant to systemic infection with S. 
Typhimurium because these mice have a wild-type natural 
resistance-associated macrophage protein 1 allele conferring 
resistance to intracellular pathogens residing within vesicles 
(49). Furthermore, a higher median lethal dose is observed 
for CBA/J mice challenged with S. Typhimurium than BALB/c 
mice (50). However, a separate study showed both the spleen 
and liver are colonized by day 15 post-infection in CBA/J mice 
infected with S. Typhimurium strain 14028 (51). Because the 
parent S. Typhimurium strain χ3761 is more virulent than 
strain 14028 in mice (52), attenuated derivatives of χ3761 such 
as those used in this study should colonize internal organs as 
well, which explains elicitation of anti-Salmonella LPS IgG 
antibodies in the present study. LPS-specific antibodies were 
detected at 6 weeks but not 3 weeks postvaccination in BALB/c 
FigUre 5 | Effect of vaccination on extraintestinal pathogenic Escherichia coli strain CFT073 ability to cause urinary tract infection in mice. Female CBA/J mice 
were immunized with PBS, χ9558(pYA3337), or χ9558(pYA4428), challenged intraurethrally with 108 CFU of CFT073, and assessed 48 h postchallenge for bacterial 
concentration in the bladder, kidney, liver, and spleen. Each experimental group contained at least 22 mice. Each dot represents an individual mouse and vertical 
dashed lines separate tissue type. Bacterial loads between groups were compared by an ANOVA followed by Tukey’s method for multiple comparisons. Below the 
x-axis for the number of E. coli-positive tissues, an asterisk (*) represents a significant (P < 0.05) difference for a vaccine treatment compared with the unvaccinated 
treatment, and two asterisks (**) represents a significant (P < 0.05) difference for χ9558(pYA4428) compared with χ9558(pYA3337) immunization as determined by 
Fisher’s exact test. Error bars represent SDs.
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mice. These antibodies may have been elicited at 3 weeks post-
vaccination, but were not detected because they were in con-
centrations below the limit of detection in the ELISA. Previous 
studies have found no response or a low LPS-specific antibody 
titer in serum 2–3  weeks postvaccination with RASV strains 
(53, 54). However, by 6  weeks postvaccination LPS-specific 
antibodies were detected in these studies (53, 54). Mucosal IgA 
antibodies to LPS and ECP were also detected but only on day 
41 in vaccinated BALB/c mice, which could not be compared 
to CBA/J mice at the same timepoint due to the UTI challenge 
timeline (Figure S2 in Supplementary Material).
Due to antigenic diversity of ExPEC strains, a vaccine should 
be designed to have broad protection. Previous studies have used 
O-antigen based vaccines against ExPEC serogroups commonly 
associated with human disease (5). One study used a tetravalent 
E. coli O-antigen vaccine to target serogroups O1, O2, O6, and 
O25 (55). Targeting specific O-groups based on prevalence in 
human patients is a rational approach, although it is limited to 
epidemiological evidence including region, as different countries 
may have different dominant serogroups (56). To assess protec-
tive potential of the RASV strains, in vitro assays were performed 
using multiple ExPEC serotypes and S. enterica serovars. Overall, 
mice vaccinated with χ9558(pYA4428) had the strongest inhibi-
tion of E. coli and Salmonella strains indicating inclusion of ECP 
may benefit broad protective ability. The mechanism of bacterial 
reduction in vaginal wash samples is unclear, but one proposed 
role of immunoglobulins in host defense includes antibodies 
binding to the bacterial surface and inhibiting its growth (57). 
Using an O1 specific monoclonal IgG antibody, Schauer et al. 
(58) found growth inhibition of Cronobacter turicensis after 2 h 
of incubation in an antibody concentration-dependent manner, 
independent of agglutination. A separate study found reduced 
growth of E. coli when incubated with IgY purified from egg 
yolk of White Leghorn hens immunized with formaldehyde-
killed E. coli compared to IgY from unimmunized hens (59). 
RASVs eliciting elevated levels of anti-E. coli and Salmonella 
antibodies may have contributed to reduced bacterial levels in 
the in vitro assays. Other possibilities that may have accounted 
for differences in bacterial levels include transient differences 
in antimicrobial peptides in the samples collected, and reduced 
survival from complement-mediated effects instead of reduced 
bacterial growth. In addition, antibodies binding to pilus pro-
teins may have caused agglutination of bacteria that was not 
detected in bacterial plating leading to an artificially low level 
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in samples from immunized mice. Future studies could investi-
gate the mechanisms responsible for the reduction in bacterial 
levels observed to determine whether these were biologically 
significant.
Recombinant attenuated Salmonella vaccines can be deliv-
ered orally which make them easy to administer to those at 
risk for ExPEC infection such as adults >50 years old, patients 
undergoing genitourinary surgery, and residents of long-term 
healthcare facilities (5). Concerns have been raised over oral 
vaccines negatively impacting the microbiome (60). However, 
recent studies have shown vaccination with a live attenu-
ated Salmonella strain or conserved E. coli antigens had no 
influence on the intestinal microbiome (61, 62). Herein, the 
vaginal wash assay showed that vaccination with the RASV 
delivering ECP had a differential effect on commensal E. coli, 
which indicates vaccination could inhibit some commensal 
E. coli commonly found in the vaginal tract, but may be 
replaced by other strains that are not affected, such as the E. coli 
Nissle 1917.
Vaccines against human ExPEC-associated diseases have 
been tested in murine models to evaluate ability to protect 
against infection (36, 46–48). Previously, we found EcpA and 
EcpD recombinant antigens elicited protection in a lethal 
BALB/c mouse sepsis model (14). A separate study used a 
similar approach to the current strategy by selecting YncE as 
a vaccine antigen, which is highly conserved in E. coli (63). 
This study found reduction, but not elimination, of E. coli in 
the blood and organs of mice following intravenous challenge 
with CFT073. In the current study using a mouse sepsis model, 
vaccination with χ9558(pYA3337) but not χ9558(pYA4428) 
reduced bacterial loads in the spleen compared with unvac-
cinated mice, but no significant differences were found in the 
blood or liver between treatments. The reason for the inability of 
χ9558(pYA4428) to provide strong protection against CFT073 
could be due to a lack of ECP synthesis in CFT073 during 
challenge. In previous studies, we found different protection 
levels in mice challenged with CFT073 grown in different 
conditions, and different growth conditions yielded different 
ECP profiles (10, 14). For χ9558(pYA3337) immunization, 
Salmonella LPS and core antigens may have elicited antibodies 
that are providing protection. Anti-core LPS antibodies raised 
in mice have been reported to bind both E. coli and Salmonella 
strains (64). Structurally, all S. enterica serotypes except 
Arizonae have identical LPS core structures, and for E. coli five 
different known core structures exist (65). Similarities between 
Salmonella and E. coli LPS cores and the elicitation of anti-LPS 
antibodies from vaccination could account for reduced loads in 
χ9558(pYA3337) vaccinated mice. In addition, antibody titer 
against LPS was slightly elevated in χ9558(pYA3337) mouse 
serum at day 41 compared with χ9558(pYA4428) and may 
account for protection seen with χ9558(pYA3337) vaccination. 
Although a significant difference was found in the spleen of 
χ9558(pYA3337) immunized mice, an early endpoint was used 
in the sepsis challenge, which may not translate to significant 
improvements in survival. This endpoint was used to determine 
bacterial loads in internal organs based on previous studies 
(35, 36). Future studies could assess whether reductions in 
bacterial loads correspond to significant improvements in 
survival.
In addition to the mouse sepsis model, CBA/J mice were 
used to assess vaccine protection against UTI. Both RASV 
strains were effective in reducing bacterial loads in the blad-
ders of vaccinated mice. Inclusion of ECP was also significant 
when analyzing the number of E. coli-positive bladder and 
liver samples. Since IgA antibodies were not detected in 
immunized mice, this protection could be conferred by a 
systemic immunity type response. The IgG response was 
similar between RASV strains, and may account for why a 
similar level of protection was observed between RASV 
immunizations. Also, RASV strains carry pathogen-associated 
molecular patterns (e.g., flagella and LPS) that induce innate 
immunity (66). Recently, Powell et al. (67) showed that RASV 
strains, including those derived from χ3761, elicit distinct 
innate immune responses in mice. In our study, induction of 
innate immune cells likely played a role in reducing severity 
of sepsis and UTI in RASV immunized mice compared with 
unvaccinated mice.
Interestingly, the in  vitro assays showed that challenge 
strain CFT073 was significantly reduced compared with the 
unvaccinated group in vaginal wash samples but not in sera 
from χ9558(pYA4428) immunized mice. This parallels the sig-
nificant difference found in the mouse UTI model and the lack 
of significant differences observed in the sepsis challenge. 
Contrary to CFT073, we found reduced levels of other ExPEC 
strains, including the multidrug resistant ExPEC strain JJ1886 
in bacterial inhibition assays. Additional ExPEC strains could 
be assessed in the mouse sepsis model in future studies to deter-
mine whether RASV immunization can provide stronger pro-
tection against different ExPEC, specifically those of sequence 
type 131 which are disseminated globally (5).
In summary, we found ECP proteins can be synthesized using 
a single plasmid as surface antigens on a RASV strain. Both RASV 
strains elicited an antibody response in mice, although it was 
detectable sooner with χ9558(pYA4428) for some antigens. The 
results suggest that the RASV alone or containing ECP showed 
potential of bacterial inhibition as assessed in in vitro assays and 
provided protection against in  vivo UTI in the bladder. Future 
studies should optimize the ExPEC antigens displayed by the 
RASV strain for a stronger immune response and enhanced 
protection against ExPEC infection.
eThics sTaTeMenT
This study was carried out in accordance with the recommen-
dations of Arizona State University Institutional Animal Care 
and Use Committee. The protocol (#1168R) was approved by 
the Arizona State University Institutional Animal Care and Use 
Committee. Six-week-old female BALB/c mice (Charles River 
Laboratories, Wilmington, MA, USA) and 4-week-old female 
CBA/J mice (Jackson Laboratories, Bar Harbor, ME, USA) 
were obtained for infection experiments. Mice were acclimated 
for 7  days before experiments began. During the experiments, 
animals were monitored twice daily by our team, animal caretak-
ers, and further inspected by a veterinarian.
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